Current Report Filing (8-k)
11 November 2021 - 8:03AM
Edgar (US Regulatory)
0001769804
false
0001769804
2021-11-09
2021-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 9, 2021
AUGMEDIX,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-56036
|
|
83-3299164
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
111
Sutter Street, Suite 1300, San Francisco, California 94104
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (888) 669-4885
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value per share
|
|
AUGX
|
|
The Nasdaq
Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
On
November 9, 2021, Augmedix, Inc., a Delaware corporation (the “Company”), issued a press release announcing
its partnership with the National Cooperative of Health Networks Association, a national professional membership organization comprised
exclusively of health networks and strategic partners. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein
by reference.
On
November 9, 2021, a presentation entitled “Augmedix Investor Presentation November 2021” was made available on the Presentations
page of the Company’s website at https://ir.augmedix.com/company-information/presentations. The presentation is furnished as Exhibit
99.2 and is incorporated herein by reference.
The
information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibits 99.1 and 99.2 are deemed to be “furnished”
and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item
7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any filing
under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AUGMEDIX,
INC.
|
|
|
|
Dated:
November 9, 2021
|
By:
|
/s/
Paul Ginocchio
|
|
|
Paul
Ginocchio
|
|
|
Chief
Financial Officer
|
2
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Apr 2023 to Apr 2024